Skip to main content

CytoDyn Inc.

corporate_fare Company Profile

CytoDyn Inc.

CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Exchange: OTCSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed CYDY - Latest Insights

CYDY
Apr 22, 2026, 5:21 PM EDT
Filing Type: S-1
Importance Score:
8
CYDY
Apr 08, 2026, 5:15 PM EDT
Filing Type: 424B3
Importance Score:
9
CYDY
Apr 08, 2026, 8:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
CYDY
Mar 25, 2026, 5:16 PM EDT
Filing Type: 424B3
Importance Score:
8
CYDY
Mar 24, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
CYDY
Mar 09, 2026, 5:15 PM EDT
Filing Type: 424B3
Importance Score:
8
CYDY
Mar 05, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
8
CYDY
Mar 05, 2026, 8:31 AM EST
Source: Reuters
Importance Score:
8
CYDY
Jan 09, 2026, 5:15 PM EST
Filing Type: 424B3
Importance Score:
9
CYDY
Jan 09, 2026, 8:30 AM EST
Filing Type: 10-Q
Importance Score:
9